Clinical data | |
---|---|
Trade names | Buscopan, others |
Other names | scopolamine butylbromide, butylscopolamine bromide (JAN JP) |
License data | |
Routes of administration | By mouth, rectal, intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | <1% |
Protein binding | Low |
Elimination half-life | 5 hours |
Excretion | Kidney (50%) and fecal[3] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.005.223 |
Chemical and physical data | |
Formula | C21H30BrNO4+ |
Molar mass | 440.378 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Hyoscine butylbromide, also known as scopolamine butylbromide[4] and sold under the brandname Buscopan among others,[5] is an anticholinergic medication used to treat abdominal pain, esophageal spasms, bladder spasms, biliary colic,[6] and renal colic.[7][8] It is also used to improve excessive respiratory secretions at the end of life.[9] Hyoscine butylbromide can be taken by mouth, injection into a muscle, or into a vein.[5]
Side effects may include sleepiness, vision changes, dry mouth, rapid heart rate, triggering of glaucoma, and severe allergies.[7] Sleepiness is uncommon.[10] It is unclear if it is safe in pregnancy.[5] It appears safe in breastfeeding.[11] Greater care is recommended in those with heart problems.[12] It is an anticholinergic agent,[5] which does not have much effect on the brain.[13]
Hyoscine butylbromide was patented in 1950, and approved for medical use in 1951.[14] It is on the World Health Organization's List of Essential Medicines.[15] It is not available for human use in the United States,[16] and a similar compound methscopolamine may be used instead.[17] It is manufactured from hyoscine - also known as scopolamine - which occurs naturally in a variety of plants in the nightshade family, Solanaceae,[18] including deadly nightshade (Atropa belladonna).[19]
It is available in the United States only for the medical treatment of horses.[2]
hyoscine butylbromide injection should be used with caution in patients with cardiac disease